Nikolaus Romani

Nikolaus Romani

Auto-generated profile, based on publicly available information

Nikolaus Romani

Medical University of Innsbruck

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 1992 in Journal of Experimental Medicine
Verified
Journal Article
Open access
KIK Inaba
K Inaba
MIM Inaba
M Inaba
NRN Romani
N Romani
HAH Aya
H Aya
MDM Deguchi
M Deguchi
RSR M Steinman
R M Steinman
Antigen-presenting, major histocompatibility complex (MHC) class II-rich dendritic cells are known to arise from bone marrow. However, marrow lacks mature dendritic cells, and substantial numbers of proliferating less-mature cells have yet to be identified. The methodology for inducing dendritic cell growth that was recently described for mouse blood now has been modified to MHC class II-negative precursors in marrow. A key step is to remove the majority of nonadherent, newly formed granulocytes by gentle washes during the first 2-4 d of culture. This leaves behind proliferating clusters that are loosely attached to a more firmly adherent "stroma." At days 4-6 the clusters can be dislodged, isolated by 1-g sedimentation, and upon reculture, large numbers of dendritic cells are released. The latter are readily identified on the basis of their distinct cell shape, ultrastructure, and repertoire of antigens, as detected with a panel of monoclonal antibodies. The dendritic cells express high levels of MHC class II products and act as powerful accessory cells for initiating the mixed leukocyte reaction. Neither the clusters nor mature dendritic cells are generated if macrophage colony-stimulating factor rather than granulocyte/macrophage colony-stimulating factor (GM-CSF) is applied. Therefore, GM-CSF generates all three lineages of myeloid cells (granulocytes, macrophages, and dendritic cells). Since > 5 x 10(6) dendritic cells develop in 1 wk from precursors within the large hind limb bones of a single animal, marrow progenitors can act as a major source of dendritic cells. This feature should prove useful for future molecular and clinical studies of this otherwise trace cell type.

1 February 1999 in Journal of Immunological Methods
Verified
Journal Article
Closed access
MLManfred B Lutz
Manfred B Lutz
NKNicole Kukutsch
Nicole Kukutsch
AOAlexandra L.J Ogilvie
Alexandra L.J Ogilvie
SRSusanne Rößner
Susanne Rößner
FKFranz Koch
Franz Koch
GSGerold Schuler
Gerold Schuler

1 July 1994 in Journal of Experimental Medicine
Verified
Journal Article
Open access
NRN Romani
N Romani
SGS Gruner
S Gruner
DBD Brang
D Brang
EKE Kämpgen
E Kämpgen
ALA Lenz
A Lenz
GSG Schuler
G Schuler
CD34+ cells in human cord blood and marrow are known to give rise to dendritic cells (DC), as well as to other myeloid lineages. CD34+ cells are rare in adult blood, however, making it difficult to use CD34+ cells to ascertain if DC progenitors are present in the circulation and if blood can be a starting point to obtain large numbers of these immunostimulatory antigen-presenting cells for clinical studies. A systematic search for DC progenitors was therefore carried out in several contexts. In each case, we looked initially for the distinctive proliferating aggregates that were described previously in mice. In cord blood, it was only necessary to deplete erythroid progenitors, and add granulocyte/macrophage colony-stimulating factor (GM-CSF) together with tumor necrosis factor (TNF), to observe many aggregates and the production of typical DC progeny. In adult blood from patients receiving CSFs after chemotherapy for malignancy, GM-CSF and TNF likewise generated characteristic DCs from HLA-DR negative precursors. However, in adult blood from healthy donors, the above approaches only generated small DC aggregates which then seemed to become monocytes. When interleukin 4 was used to suppress monocyte development (Jansen, J. H., G.-J. H. M. Wientjens, W. E. Fibbe, R. Willemze, and H. C. Kluin-Nelemans. 1989. J. Exp. Med. 170:577.), the addition of GM-CSF led to the formation of large proliferating DC aggregates and within 5-7 d, many nonproliferating progeny, about 3-8 million cells per 40 ml of blood. The progeny had a characteristic morphology and surface composition (e.g., abundant HLA-DR and accessory molecules for cell-mediated immunity) and were potent stimulators of quiescent T cells. Therefore, large numbers of DCs can be mobilized by specific cytokines from progenitors in the blood stream. These relatively large numbers of DC progeny should facilitate future studies of their Fc epsilon RI and CD4 receptors, and their use in stimulating T cell-mediated resistance to viruses and tumors.

1 September 1996 in Journal of Immunological Methods
Verified
Journal Article
Closed access
NRNikolaus Romani
Nikolaus Romani
DRDaniela Reider
Daniela Reider
MHMarion Heuer
Marion Heuer
SESusanne Ebner
Susanne Ebner
EKEckhart Kämpgen
Eckhart Kämpgen
GSGerold Schuler
Gerold Schuler

1 May 2005 in Immunity
Verified
Journal Article
Closed access
AKAdrien Kissenpfennig
Adrien Kissenpfennig
SHSandrine Henri
Sandrine Henri
BDBertrand Dubois
Bertrand Dubois
CLCorinne Laplace-Builhé
Corinne Laplace-Builhé
PPPierre Perrin
Pierre Perrin
BMBernard Malissen
Bernard Malissen

1 August 1996 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
FKF Koch
F Koch
USU Stanzl
U Stanzl
PJP Jennewein
P Jennewein
KJK Janke
K Janke
CHC Heufler
C Heufler
GSG Schuler
G Schuler
We have shown previously that dendritic cells (DC) produce IL-12 upon interaction with CD4+ T cells. Here we ask how this IL-12 production is induced and regulated. Quantitative PCR and in situ hybridization for IL-12 p40 and an ELISA specific for the p70 heterodimer were used to determine IL-12 production. We demonstrate that ligation of either CD40 or MHC class II molecules independently trigger IL-12 production in DC, and that IL-12 production is downregulated by IL-4 and IL-10. The levels of bioactive IL-12 that can be released by triggering with an anti-CD40 mAb or with a T cell hybridoma are high (range 260-4700 pg/ml from 1 X 10(6) DC in 72 h). The CD40-mediated pathway indicates that IL-12 production is induced in DC upon interaction with activated, CD40 ligand-expressing helper T cells, even in the absence of cognate antigen recognition. Side-by-side comparison of IL-12 production, and blocking experiments employing an anti-CD40 ligand mAb, suggest that the CD40-mediated pathway is quantitatively more significant than induction via the MHC class II molecule. The importance of the CD40/CD40 ligand interaction for IL-12 induction in DC likely contributes to the recent finding that mice lacking the CD40 ligand are impaired in mounting Th1 type cell-mediated immune responses.